Xiang Kun, Catanzaro John N, Elayi Claude, Esquer Garrigos Zerelda, Sohail Muhammad R
Cardiology, University of Florida College of Medicine, Gainesville, USA.
Cardiology, University of Florida College of Medicine - Jacksonville, Jacksonville, USA.
Cureus. 2021 Feb 2;13(2):e13088. doi: 10.7759/cureus.13088.
Cardiac-implantable electronic device (CIED) infections are associated with significant morbidity and mortality. In this review, we describe the risk factors and pathogenesis of CIED infections and review the rationale and the evidence for the use of antibiotic-eluting envelopes (ABEs) in patients at increased risk for CIED infections.
The majority of CIED infections are caused by staphylococci that involve generator pocket and occur due to contamination of the device or the pocket tissues at the time of implantation. Clinical trials have shown that extending the duration of post-operative systemic antibacterial therapy is not beneficial in reducing CIED infection rate. However, ABEs that reduce device migration after implantation and provide sustained local delivery of prophylactic antibiotics at the pocket site, may provide benefit in reducing infection. Currently, there are two types of commercially available CIED envelope devices in the United States. The first ABE device (TYRX™, Medtronic Inc., Monmouth Junction, NJ) is composed of a synthetic absorbable mesh envelope that elutes minocycline and rifampin and has been shown to reduce CIED pocket infections in a large multi-center randomized clinical trial. The second ABE device (CanGaroo-G™, Aziyo Biologics, Silver Spring, MD) is composed of decellularized extracellular matrix (ECM) and was originally designed to stabilize the device within the pocket, limiting risk for migration or erosion, and providing a substrate for tissue ingrowth in a preclinical study. This device has shown promising results in a preclinical study with local delivery of gentamicin. Compared with artificial materials, such as synthetic surgical mesh, biologic ECM has been shown to foster greater tissue integration and vascular ingrowth, a reduced inflammatory response, and more rapid clearance of bacteria.
ABE devices provide sustained local delivery of antibiotics at the generator pocket site and appear beneficial in reducing CIED pocket infections. Given the continued increase in the use of CIED therapy and resultant infectious complications, innovative approaches to infection prevention are critical.
心脏植入式电子设备(CIED)感染与严重的发病率和死亡率相关。在本综述中,我们描述了CIED感染的危险因素和发病机制,并综述了在CIED感染风险增加的患者中使用抗生素洗脱包膜(ABE)的基本原理和证据。
大多数CIED感染由葡萄球菌引起,累及发生器囊袋,是由于植入时设备或囊袋组织受到污染所致。临床试验表明,延长术后全身抗菌治疗时间对降低CIED感染率并无益处。然而,ABE可减少植入后设备移位,并在囊袋部位持续局部递送预防性抗生素,可能有助于降低感染风险。目前,美国有两种市售的CIED包膜装置。第一种ABE装置(TYRX™,美敦力公司,新泽西州蒙茅斯章克申)由一种可吸收的合成网状包膜组成,可洗脱米诺环素和利福平,在一项大型多中心随机临床试验中已证明可减少CIED囊袋感染。第二种ABE装置(CanGaroo-G™,Aziyo生物制品公司,马里兰州银泉)由脱细胞细胞外基质(ECM)组成,最初设计用于在囊袋内稳定设备,限制移位或侵蚀风险,并在一项临床前研究中为组织向内生长提供基质。该装置在一项局部递送庆大霉素的临床前研究中显示出有前景的结果。与人工材料(如合成外科网片)相比,生物ECM已证明可促进更大程度的组织整合和血管向内生长、减少炎症反应并更快速清除细菌。
ABE装置在发生器囊袋部位持续局部递送抗生素,似乎有助于降低CIED囊袋感染。鉴于CIED治疗的使用持续增加以及由此产生的感染并发症,创新的预防感染方法至关重要。